 SOUTH PLAINFIELD, N.J., April 1, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced that a 20 million milestone payment was triggered by the first commercial sale of EvrysdiTM risdiplam in the European Union under its License and Collaboration Agreement with Roche. 